GlobeNewswire

Resolutions of Talenom Plc’s Annual General Meeting and organisational meeting of the Board of Directors

Share

Talenom Plc, Stock exchange release, 3 March 2021 at 13:15 EET

Resolutions of Talenom Plc’s Annual General Meeting and organisational meeting of the Board of Directors

The Annual General Meeting of Talenom Plc was held on 3 March 2021 in Helsinki. Shareholders and their proxy representatives could participate in the Annual General Meeting and exercise their shareholder rights only by voting in advance and by submitting counterproposals and asking questions in advance. It was not possible to participate in the meeting in person at the meeting venue. The exceptional procedure for the meeting was based on the temporary legislative act to limit the spread of the Covid-19 pandemic approved by the Finnish Parliament. 

The Annual General Meeting adopted the financial statements for the financial year ended 31 December 2020 and resolved to discharge from liability the members of the Board of Directors and the CEO.

The use of the profit shown on the balance sheet and the payment of dividends

The Annual General Meeting resolved that a dividend of EUR 0.15 per share will be paid for the financial year 1 January–31 December 2020. Undistributed profits shall remain in equity.The dividend will be paid to shareholders who on the dividend record date, 5 March 2021, are registered as shareholders in the company’s shareholders’ register maintained by Euroclear Finland Ltd. The dividend payment date is 12 March 2021. Dividend shall not be paid to treasury shares held by the company.

Remuneration Report for governing bodies

The Remuneration Report of governing bodies was presented to the Annual General Meeting. The Annual General Meeting resolved to support the Remuneration Report.

The number and remuneration of members of the Board of Directors

It was resolved that a remuneration of EUR 6,000 per month will be paid to the Chairman of the Board of Directors and EUR 2,000 per month to other members of the Board of Directors. Additionally, the travel expenses of the members of the Board of Directors will be compensated in accordance with the company’s travel policy. The Annual General Meeting resolved that the number of the members of the Board of Directors shall be six.

Election of members of the Board of Directors

The Annual General Meeting elected Harri Tahkola, Mikko Siuruainen, Olli Hyyppä, Johannes Karjula and Sampsa Laine as the members of the Board of Directors for a new term of office and elected Elina Tourunen as new member of the Board of Directors. 

Election and remuneration of the auditor

The Board of Directors re-elected KPMG Oy Ab, authorised public accountant organisation, as the auditor of the company. Juho Rautio, authorised public accountant, will continue as the principal auditor. The term of the auditor will run until the end of the next Annual General Meeting. The auditor will be remunerated according to the reasonable invoice approved by the company.

Authorising the Board of Directors to decide on the repurchase of own shares

The Annual General Meeting authorised the Board of Directors to resolve on the repurchase of a maximum of 150,000 own shares in the company in one or several tranches using the company’s unrestricted shareholders’ equity. The shares will be repurchased otherwise than in proportion to the shareholdings of the shareholders in public trading arranged by Nasdaq Helsinki Ltd for the market price at the moment of purchase.

The authorisation remains valid until the closing of the next Annual General Meeting, but no longer than until 30 June 2022. The authorisation replaces the previous authorisation to repurchase own shares granted by the Annual General Meeting on 25 February 2020.

Authorising the Board of Directors to resolve on share issues and issues of option rights and other special rights entitling to shares

The Annual General Meeting authorised the Board of Directors to resolve on the issuance of shares and the issuance of special rights entitling to shares as referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act in one or several tranches, either against payment or without payment.

The aggregate amount of shares to be issued, including the shares to be received based on special rights, must not exceed 2,100,000 shares. The Board of the Directors may resolve to issue new shares or to transfer own shares possibly held by the company. The maximum amount of the authorisation corresponds to approximately 4.8 per cent of all shares in the company.

The Board of Directors is authorised to decide on all other matters related to the issuance of shares and special rights entitling to shares, including the right to deviate from the pre-emptive right of shareholders to subscribe for shares to be issued. The authorisation is used for the purposes of paying purchase prices of corporate acquisitions, share issues directed to personnel or share award schemes or to issue share options or for other purposes decided by the Board of Directors.

The authorisation remains valid until the closing of the next Annual General Meeting, but no longer than until 30 June 2022. The authorisation revokes all previous unused authorisations to resolve on the issuance of shares, option rights and other special rights entitling to shares.

Organisational meeting of the Board of Directors


In its organisational meeting held after the Annual General Meeting, the Board of Directors of Talenom Plc re-elected Harri Tahkola as Chairman of the Board of Directors. The Board of Directors has evaluated the independence of its members of the company and of significant shareholders as follows:

  •  Harri Tahkola is not considered to be independent of the company based on an overall assessment. In addition, he is not considered to be independent of significant shareholders, as he owns more than 10% of the shares in the company.
  •  Mikko Siuruainen is considered to be independent of the company and its significant shareholders.
  •  Olli Hyyppä is considered to be independent of the company and its significant shareholders.
  •  Johannes Karjula is considered to be independent of the company and its significant shareholders.

  •  Sampsa Laine is considered to be independent of the company and its significant shareholders.

  •  Elina Tourunen is considered to be independent of the company and its significant shareholders.


TALENOM PLC
BOARD OF DIRECTORS                               


Further information:


Otto-Pekka Huhtala
CEO
Talenom Plc
tel. +358 40 703 8554

Talenom is an agile and progressive accounting firm established in 1972. Our business idea is to make day-to-day life easier for entrepreneurs with the easiest-to-use digital tools on the market and highly automated services. In addition to comprehensive accounting services, we support our customers’ business with a wide range of expert services as well as financing and banking services. Our vision is to provide unbeatable accounting and banking services for SMEs.

Talenom has a history of strong growth – the average annual increase in net sales was approximately 15.5% between 2005 and 2020. At the end of 2020, Talenom had 912 employees in Finland and Sweden at a total of 47 locations. Talenom’s share is quoted on the main list of the Helsinki Stock Exchange.

DISTRIBUTION                                   
Nasdaq Helsinki
Main media
www.talenom.fi


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million23.4.2021 07:00:00 CEST | Press release

GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million Schiphol, the Netherlands – 23 April 2021. GrandVision N.V. publishes its First Quarter 2021 trading update. Due to the exceptional nature of the year 2020, GrandVision will also include in the present press release comparisons versus 2019. Highlights • GrandVision continues to show resilience in the first quarter despite the most recent COVID-19 related government restrictions in Europe and Latam • At constant exchange rates, revenue declined by -0.7% compared with 1Q20 to €899 million from €926 million in 1Q20 (1Q19: €974m) • Comparable revenue declined by -1.5% versus 1Q20 and on a 2019 basis, -10.8% versus 1Q19 • Adj. EBITA increased by 98.1% at constant exchange rates to €79 million from €41 million in 1Q20 (1Q19: €107m). Continued cost discipline, structural improvements in certain territories and improved product and price mix contributed to the underlying performance • Adj. EBITA margin at 8.8%,

Corbion appoints Aurélie Dalbiez as Chief Human Resources Officer23.4.2021 07:00:00 CEST | Press release

Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of the Executive Committee as of 1 July 2021. Mrs. Dalbiez (a French national) currently is Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career at Deutsche Bank before working for Capital International, a global investment company. CEO Olivier Rigaud commented: "I am really pleased to welcome Aurélie to the ExCo team as a seasoned HR leader who partners closely with the business to develop talent, drive culture, engagement, continuous improvement, and customer intimacy. Her appointment will also further enhance the diversity of our ExCo." Mrs. Dalbiez brings a multi-cultural background and perspective. She lived in the United States as a child, earned her university degree in International Business in Lyon, France and worked internationally throughout

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy23.4.2021 07:00:00 CEST | Press release

About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. Endometrial cancer is the most common gynecologic can

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies23.4.2021 06:01:00 CEST | Press release

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium;23April 2021;06.01 CET; –Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partnerGilead Sciences K.K. (“Gilead”) and Eisai Co., Ltd. (“Eisai”)today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC).Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating the efficacy and safety of filgotinib for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis who have had a

Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results23.4.2021 02:00:00 CEST | Press release

Camposol Holding PLC will announce the results for the full year 2020 on Thursday, April 29, 2021. In connection with the release, a telephone conference will be held at 9:30 a.m. (Lima) as described below. The presentation will be published at 8:30 a.m. (Lima) and will be available on the Company's website. In connection with the earnings release Samuel Dyer Coriat, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:30 a.m. (Lima). To participate in the conference call, please use the following numbers: London, UK Local +0800 028 8438 US/Canada International +1 409 981 0728 Zurich, Switzerland, Local +044 580 1740 Oslo, Norway, Local +47 8001 6162 Colombia, National Free Phone +01 800 518 5094 Chile, National Free Phone +56 800 914 686 Peru, National Free Phone +51 0800 71470 Participants will be asked for their name and conference ID. The Camposol conference ID is: 2466977 Audio access for the meeting is available by dialing the above-m

CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release

•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and